A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 256,700 shares of AUTL stock, worth $854,811. This represents 0.0% of its overall portfolio holdings.

Number of Shares
256,700
Previous 31,100 725.4%
Holding current value
$854,811
Previous $198,000 351.01%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.33 - $5.68 $751,248 - $1.28 Million
225,600 Added 725.4%
256,700 $893,000
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $8,084 - $10,935
1,500 Added 5.07%
31,100 $198,000
Q4 2023

Feb 14, 2024

BUY
$2.13 - $6.63 $9,585 - $29,835
4,500 Added 17.93%
29,600 $190,000
Q3 2023

Nov 14, 2023

SELL
$2.32 - $3.36 $3,016 - $4,368
-1,300 Reduced 4.92%
25,100 $58,000
Q2 2023

Aug 14, 2023

BUY
$1.64 - $3.21 $20,828 - $40,767
12,700 Added 92.7%
26,400 $62,000
Q1 2023

May 15, 2023

BUY
$1.75 - $2.25 $23,975 - $30,825
13,700 New
13,700 $25,000
Q2 2021

Aug 16, 2021

SELL
$4.78 - $7.96 $66,442 - $110,644
-13,900 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$5.49 - $9.36 $76,311 - $130,103
13,900 New
13,900 $80,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $303M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.